Merck receives positive CHMP opinion for Keytruda® (pembrolizumab) in triple-negative breast cancer

Apr 25, 2022

Merck announced that it received a positive CHMP opinion for its anti-PD-1 therapy Keytruda® (pembrolizumab) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy in adjuvant treatment after surgery for adults with locally advanced, or early-stage triple-negative breast cancer (TNBC) at high risk of recurrence.

Print Page Mail Article